November 7, 2016
Celyad's NKR phase I trial shows encouraging results
The first data analysis of the NKR-2 Phase I trial, run by the Belgia’s biopharmaceutical company Celyad, shows encouraging results
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
November 4, 2016
Lartruvo-soft tissue sarcoma drug to sell in U.S.
FDA granted accelerated approval to Lartruvo (olaratumab) injection, in combination with doxorubicin, for the treatment of adult patients…
November 3, 2016
Horizon’s urea cycle disorder drug to sell in Canada
Horizon Pharma has announced that Ravicti (glycerol phenylbutyrate) Oral Liquid is now available in Canada through its affiliate….
November 3, 2016
Alkermes awards $1M to support people affected by mental health
Alkermes, a global biopharmaceutical company developing medicines for the treatment of central nervous system…
November 2, 2016
Eli Lilly, Incyte’s rheumatoid arthritis drug studies show positive effect
Eli Lilly and Company and Incyte Corporation have announced on Wednesday that new data from RA-BEACON – a pivotal phase 3 study…
November 2, 2016
Allergan announces $10 B accelerated share repurchase, initiation of cash dividend in 2017
Allergan has completed its initial $5 billion in share repurchases under its previously announced share repurchase program…
November 2, 2016
Abzena, Gilead drop Chron Disease drug after Phase II study
Abzena has issued a statement in which it notes that during the conference call to accompany Gilead Sciences Inc.’s (‘Gilead’) announcement of third quarter
November 2, 2016
Chronix Biomedical looking to distinguish prostate cancer from BPH and prostatitis
Chronix Biomedical looking to distinguish prostate cancer from BPH and prostatitis
November 1, 2016
Pfizer to discontinue two ongoing cardiovascular studies
Pfizer announced today the discontinuation of the global clinical development program for bococizumab…
November 1, 2016
Novartis gets FDA Priority Review for first-line treatment of advanced breast cancer
Novartis gets FDA Priority Review for first-line treatment of HR+/HER2-advanced breast cancer